Shukra Pharmaceuticals (524632) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
13 Aug, 2025Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2025, and reviewed business operations.
Financial highlights
Revenue from operations for Q1 FY26 was ₹539.11 lakhs, up from ₹317.80 lakhs year-over-year.
Total income for the quarter was ₹650.08 lakhs, compared to ₹389.56 lakhs in Q1 FY25.
Net profit for the quarter stood at ₹102.96 lakhs, up from ₹48.53 lakhs in the same quarter last year.
Basic and diluted EPS for the quarter were ₹0.02, compared to ₹0.11 in Q1 FY25.
Outlook and guidance
Financial statements prepared in accordance with Indian Accounting Standards and SEBI regulations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Shukra Pharmaceuticals
- Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment.524632
Q1 26/27 - Revenue and net profit surged year-over-year, with robust equity and no debt defaults.524632Q4 25/26
- Q3 FY26 revenue and profit surged, with strong audit review and MD re-appointment.524632Q3 25/26
- Q2 FY26 saw higher revenue, profit, and cash, with clean auditor review and no complaints.524632Q2 25/26
- Q2 FY2024-25 revenue grew, but net profit and EPS fell; cash reserves increased.524632Q2 24/25
- Q1 FY25 saw a significant drop in revenue and profit, but auditors raised no concerns.524632Q1 24/25
- FY25 revenue and profit declined sharply, but financial position and compliance remain strong.524632Q4 24/25
- Quarterly profit and revenue surged, with strengthened audit oversight.524632Q3 24/25